Abstract: An anti-epileptic agent for use in the treatment of a neurological disorder other than epilepsy characterised in that the anti-epileptic agent is the sole active agent and that the daily dose of the anti-epileptic is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
Abstract: In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to 3-bromopyruvate (3-BrPA) are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with 3-BrPA are provided. In some aspects, compositions useful for subjects with cancers that express increased levels of MCT1 are provided. In some aspects, methods of treating subjects with cancers that express increased levels of MCT1 are provided. In some aspects, methods of identifying anti-tumor agents the efficacy of which is at least in part dependent on transporter-mediated uptake are provided.
Type:
Application
Filed:
October 4, 2013
Publication date:
May 22, 2014
Inventors:
Kivanc Birsoy, David M. Sabatini, Richard Possemato, Tim Wang
Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.
Abstract: Composition and method for production of peroxycarboxylic acid solutions for various disinfection and cleaning compositions that utilizes non-equilibrium peroxycarboxylic acid. More specifically compositions comprise peracetic acid (PAA) and methods for making non-equilibrium PAA are provided. Frozen compositions useful as antimicrobial ice are provided.
Type:
Application
Filed:
June 3, 2013
Publication date:
May 15, 2014
Inventors:
Wayne E. BUSCHMANN, Andrew S. Del Negro
Abstract: This invention relates to a buffering composition for the topical or internal treatment of animal tissues to buffer and normalize the pH of the cellular environment while also affecting specific cellular membrane ion channels as a method to affect inflammation, proteases, reactive oxygen species and free radicals, the composition containing a pharmaceutically-effective concentration of an acid and its base salt, where the counterions of the base salt are potassium and at least one of cesium and rubidium, or all three.
Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.
Type:
Application
Filed:
October 23, 2013
Publication date:
May 15, 2014
Applicant:
PULMATRIX, INC.
Inventors:
Michael M. LIPP, Robert W. CLARKE, David L. HAVA, Richard BATYCKY, John HANRAHAN
Abstract: The present invention relates to a composition comprising a synergetic mixture of flavorings or flavoring substances and organic acids. Moreover, the present invention relates to the use of said composition as a preservative for animal foodstuffs and additives intended preferably for monogastric animals.
Abstract: Antimicrobial compositions are provided comprising a pharmaceutically acceptable organic acid and a pharmaceutically acceptable surfactant. This synergistic combination allows compositions to be formulated at low concentrations that have efficacy in reducing bacterial counts by greater than 3 log within 5 minutes of contact while preserving the organoleptic properties of treated foods, including fresh produce. Also provided are methods for the use of the compositions to reduce the microbial load on the surfaces of foodstuffs, processed food products, and the hard surfaces of food preparation machinery, tools, benches, and the like.
Type:
Grant
Filed:
February 1, 2012
Date of Patent:
May 13, 2014
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: An inverse latex including from 20% to 70% by weight and preferably from 25% to 50% by weight of a branched or crosslinked polyelectrolyte, characterized in that the polyelectrolyte is a copolymer of 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified with acrylamide and optionally one or more monomers chosen from monomers containing a partially or totally salified weak acid function and/or from neutral monomers other than acrylamide, the production process including the control of the pH in the initial aqueous phase; Cosmetic, dermopharmaceutical or pharmaceutical composition including the inverse latex directly obtained by the process.
Type:
Application
Filed:
January 13, 2014
Publication date:
May 8, 2014
Applicants:
Scott Bader Company Limited, Societe D'Exploitation De Produits Pour Les Industries Chimiques Seppic
Inventors:
Olivier BRAUN, Paul MALLO, Audrey BONNARDEL, Francois GUY
Abstract: The present invention relates to a topical film-forming composition for the treating dermatophytosis, specifically mycoses of the feet and, in particular, for treating the symptoms associated with dermatophytosis, specifically the symptoms associated with athlete's foot. The composition is particularly suitable for treating cracking, and for promoting the healing of skin lesions caused by said inflammation. The present composition is also suitable for preventing bacterial or fungal proliferation in the damaged skin.
Abstract: The present invention is directed to methods of using inhibitors of the cytosolic form of BCAT in the treatment of cancer, rheumatoid arthritis, and bone disease.
Abstract: This invention relates to the use of an oral composition comprising Stevia extract, steviol precursors, or steviol which enhances the appearance of hair. It further relates methods of improving the appearance of hair by oral administration of an effective amount of Stevia extract, steviol precursors or steviol.
Type:
Application
Filed:
January 13, 2014
Publication date:
May 8, 2014
Applicant:
DSM IP ASSETS B.V.
Inventors:
Regina GORALCZYK, Annis O. MAYNE-MECHAN, Jenny PIUSSI, Henry RIEGER, Hasan MOHAJERI
Abstract: The present disclosure is drawn to a disinfectant system which can be used to disinfect surfaces. The system includes a first chamber containing a first solution and a second chamber containing a second solution. The first solution can include an alcohol, an organic carboxylic acid, and from 0.01 ppm, to 1,000 ppm by weight of a transition metal or alloy thereof based on the first solution weight content. The second solution can include hydrogen peroxide. The system further includes a dispenser through which the system is configured to mix and dispense the first solution and the second solution immediately before being dispensed. A peracid composition is formed upon mixing of the first and second solutions.
Abstract: Acidic oral compositions having calcium contents and effective pH-values in the area indicated by grey-tone in FIG. 2 are non-erosive in saliva and capable of stimulating saliva production, even in “dry mouth” patients. A new multi-step test method for determining erosive potential in saliva has been used for identifying the compositions.
Type:
Application
Filed:
October 24, 2013
Publication date:
May 1, 2014
Inventors:
Thorbjorg Jensdottir, Allan Bardow Jensen, Birgitte Nauntofte, Christian Buchwald
Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
Abstract: Peroxycarboxylic acid compositions having reduced hydrogen peroxide content are generated according to the invention, having enhanced antimicrobial efficacy. Simultaneously, a stable hydrogen peroxide and active oxygen coordinating compound complex is generated and has utility as a recycled bleaching component. In particular, methods of using an active oxygen coordinating compound to selectively and non-destructively remove hydrogen peroxide are provided. Preferred active oxygen coordinating compounds suitable for use with the peroxycarboxylic acid compositions include nitrogen-containing compounds, preferably urea, urea copolymers and/or derivatives, PVP, PVP copolymers and/or derivatives, and/or inorganic carbonates.
Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
Abstract: A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy.
Abstract: Treated peroxycarboxylic acid compositions and methods of using the same are provided to eliminate or reduce malodors associated therewith. Peroxycarboxylic acid compositions are treated with odor reducing agents, including various chaototropic agents. The invention further relates to methods employing the reduced odor peroxycarboxylic acid compositions.
Type:
Application
Filed:
October 26, 2012
Publication date:
May 1, 2014
Applicant:
Ecolab USA Inc.
Inventors:
Kim R. Smith, Erik C. Olson, Victor Fuk-Pong Man, Benjamin F. Reid
Abstract: A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl2(OH)6]+. The drug delivery system has use in the delivery of drugs such as 4-biphenylacetic acid, Diclofenac, Gemfibrozil, Ibuprofen, Naproxen, 2-Propylpentanoic acid and Tolfenamic acid.
Abstract: The invention is a method for attracting mosquitoes by producing a volatilized acid by combining an acid precursor with water to produce the humidified vapor acid attractant, preferably hydrogen chloride. The humidified volatilized acid can be further combined with carbon dioxide, or carbon dioxide can be simultaneously produced to attract mosquitoes. The acid precursor can be a hydrate of ferric chloride, such as ferric chloride hexahydrate. The acid precursor can be impregnated in a carrier, and can be combined with water through exposure to water vapor in the atmosphere, the intentional addition of water, or water produced by a chemical reaction.
Abstract: Methods have been developed for incorporation of peracid compounds and related compositions into a non-aqueous medium. The peracid incorporated into the non-aqueous medium is stable and keeps its chemical and antimicrobial activity for extended durations. The non-aqueous medium may be removed just prior to or during application of the peracid.
Type:
Application
Filed:
October 18, 2013
Publication date:
April 24, 2014
Applicant:
CHD Bioscience, Inc.
Inventors:
Edwin D. Neas, Michael K. Handley, Kevin S. Marchitto, Stephen T. Flock, Charles Henry
Abstract: The present invention provides methods for producing a non ?-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound. In particular, compositions of the invention provide for a mixture of an ?-keto peracid and a non ?-keto peracid that works synergistically to reduce microbes on a surface, to prevent vegetative bacteria on a surface and to heal a wound in animals or humans.
Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.
Type:
Application
Filed:
October 22, 2012
Publication date:
April 24, 2014
Applicant:
E. I. DU PONT DE NEMOURS AND COMPANY
Inventors:
ROBERT DICOSIMO, MARK SCOTT PAYNE, JOHN EDWARD GAVAGAN
Abstract: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Type:
Application
Filed:
April 12, 2013
Publication date:
April 10, 2014
Applicant:
The Regents of the University of Colorado, a body corporate
Inventors:
Daniel J. ABRAMS, Raymond BUNCH, Tom ANCHORDOQUY, Karen E. STEVENS
Abstract: The present invention relates to compounds according to formula (I) for medical use. The compounds are particularly suitable for the treatment and/or prevention of a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue. Furthermore, the invention relates to the use of said compounds for preparing a medicament and to pharmaceutical preparations comprising such compounds. The invention also relates to methods of treating or protecting patients having or being prone to develop a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue, the methods comprising administration of a therapeutically effective amount of such compounds.
Type:
Application
Filed:
December 11, 2013
Publication date:
April 10, 2014
Applicants:
ETH ZURICH, UNIVERSITY OF ZURICH
Inventors:
Ludwig K. Limbach, Inge K. Herrmann, Beatrice Beck-Schimmer, Wendelin J. Stark, Martin Urner
Abstract: Exemplary embodiments of solutions of plasma activated water and peroxyacetic acid are disclosed herein. In addition, exemplary embodiments of methods for making solutions are disclosed herein. Some methods include exposing water to a plasma gas to activate the water, adding acetic acid to the activated water; and mixing the acetic acid and activated water to form a solution. Additional exemplary methods include adding acetic acid to water to form a solution, mixing solution of acetic acid and water together; and exposing the solution to a plasma gas to activate the solution. Another exemplary embodiment includes exposing water to a plasma gas to activate the water; adding an acetyl group donor to the activated water; and mixing the acetyl group donor and activated water to form a solution.
Type:
Application
Filed:
March 15, 2013
Publication date:
April 10, 2014
Applicant:
EP Technologies LLC
Inventors:
Robert Gray, Keith A. Pelfrey, Chris Fricker, James Bingham
Abstract: This invention relates to rinse-off skin conditioning compositions comprising relatively low amounts of oil/emollient and relatively low amounts of aqueous phase stabilizer/structurant. Use of unsaturated fatty acid (or at least minimum amount of unsaturated fatty acid as percentage of total fatty acid) has been found to result in unexpectedly high hydration. In a second embodiment, use of branched fatty acid (at minimum amount branched as percentage of total) also results in superior hydration. Also mixtures of unsaturated and branched fatty acids can be used. In a second embodiment, the invention relates to method of enhancing hydration using compositions as noted.
Abstract: Methods of using a non-irritant, low pH acidic composition to destroy undesirable microorganisms are described. The methods may be used on food products, food processing equipment, and in aqueous solutions.
Abstract: Here provided is a method for regulating retinal endothelial cell viability in a mammal by administering to the mammal a therapeutically effective amount of a quinic acid analog. The method may be applied to prevent, treat or cure pathological conditions of retinal endothelial cells associated with radiation retinopathy, diabetic retinopathy and chemotherapy for retinoblastoma.
Type:
Application
Filed:
November 7, 2013
Publication date:
April 3, 2014
Applicant:
The University of Tennessee Research Foundation
Inventors:
Charles Ryan Yates, Jena Steinle Smith, Duane Douglas Miller, Jordan J. Toutounchian
Abstract: The compositions and methods of this invention relate to peelable film-forming compositions that may be applied to and removed from the skin containing polyvinyl alcohols and adhesion-enhancing polymers.
Type:
Application
Filed:
September 28, 2012
Publication date:
April 3, 2014
Inventors:
Prashant Bahadur, Jeffrey M. Wu, Kamesh R. Yerramilli
Abstract: A dietary supplement or medicament comprising a substance including the chemical structure of bicyclo [3.2.1]octan or the chemical structure of kaurene. The medicament is useful for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The possible substances include steviol, isosteviol or stevioside.
Type:
Application
Filed:
June 13, 2013
Publication date:
April 3, 2014
Inventors:
Kjeld Hermansen, Soren Gregersen, Per Bendix Jeppesen
Abstract: Disclosed herein is an isolated Muscodor albus strain producing volatile organic compounds such as aristolene, 3-octanone and/or acetic acid ester, as well as cultures of said strain and compositions, metabolites and volatiles derived from said strain or culture as well as methods of obtaining said compositions, metabolites and volatiles and their methods of use for controlling pests. Also disclosed are artificial compositions having the same components and uses as the volatiles derived from the strain. A method for capturing and sampling the volatiles is also disclosed.
Type:
Application
Filed:
September 23, 2013
Publication date:
March 27, 2014
Applicant:
Marrone Bio Innovations, Inc.
Inventors:
Gary Strobel, Vu Phong Bui, Hai Su, Phyllis Himmel, Pamela Marrone, Lijuan Xing, Sarah Lewis
Abstract: The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
Abstract: The invention provides methods of improving and/or preventing one or more depression-like symptoms by administering to an individual an effective amount of calcium L-threonate. Also provided are related kits and articles of manufacture.
Abstract: The present invention relates to compositions and methods for treatment of depression, anxiety, schizophrenia, sleep disorder, or epilepsy comprising monocholine salt of succinic acid of a formula (I) or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutically acceptable salt is dicholine salt of succinic acid of a formula (II).
Abstract: A produce wash is provided that reduces or eliminates the chlorine used in treating produce and inhibits the growth of microorganisms, including bacteria and mold, on pre-harvest and post-harvest produce and extends the shelf-life of the treated produce. Methods of making and using the produce wash also are provided.
Abstract: The present invention relates in general to topical compositions having improved antimicrobial effect useful for the treatment of hyperkeratotic skin conditions. More specifically, the present invention relates to topical compositions comprising a combination of one or more alfa-hydroxy acids, urea, glycerol, and panthenol, as well as the use of such compositions for the treatment of hyperkeratotic skin conditions, in particular on the feet, and also on other body areas where thick skin is noted and where infections should be avoided.
Abstract: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for presenting the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.
Abstract: The invention relates to the use of lipooxigenase inhibitors for treating acne, particularly inflammatory acne. The inventive lipooxigenase inhibitor can be used alone or in combination with other lipooxigenase inhibitors or anti-acne active agents in a pharmaceutically suitable composition, particularly through oral and/or local-topic application.
Abstract: Disclosed herein are parenteral solutions containing 3-diethylaminoethoxy benzoyl-benzofurans, such as amiodarone, in a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of cardiac arrhythmias both supraventricular, ventricular as well as, the condition of cardiac arrest.
Abstract: The invention relates to an oleogel-forming agent which comprises at least one highly dispersed triterpene. The invention also relates to an oleogel which comprises a nonpolar liquid in an amount ranging from 80% by weight to 99% by weight based on the total weight of the oleogel and an oleogel-forming agent comprising a highly dispersed triterpene in an amount ranging from 1% by weight to 20% by weight based on the total weight of the oleogel. The invention also relates to a method for producing an oleogel.
Abstract: Compounds of the formula (I): in which A, R1, R2, X, Y and Z are defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.
Type:
Grant
Filed:
December 22, 2005
Date of Patent:
February 18, 2014
Assignee:
Merck Patent GmbH
Inventors:
Catherine Vidal, Nathalie Adje, Stéphane Yvon, Jean Jacques Zeiller
Abstract: The present invention relates to calcium salts of compounds of the general formula (I) wherein X is selected from the group consisting of CH2, S, or O; D is O or S; R8 is hydrogen or alkyl; E is an optionally substituted phenylene group; Y is a monocyclic or bicyclic substituted or unsubstituted 6-9 membered ring system which may contain one or more heteroatoms selected from N or S and which contains at least one aromatic ring; n is 0 or 1, and q is 0 or 1; with the proviso that compounds wherein X?CH2, q=0, Y=unsubstituted phenyl and E=unsubstituted phenylene are excluded; or a hydrate thereof.
Type:
Grant
Filed:
July 1, 2011
Date of Patent:
February 18, 2014
Assignee:
4SC MG
Inventors:
Aldo Ammendola, Julia Diederichs, Johann Leban, Daniel Vitt
Abstract: A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure.
Abstract: The present invention relates to assays for monitoring activity of YcfD activity, in particular, to assays for identifying modulators of YcfD activity. The present invention also relates to the use of YcfD inhibitors as antibiotics. The invention also relates to methods for introducing hydroxyarginine residues into proteins.
Type:
Application
Filed:
January 30, 2012
Publication date:
February 13, 2014
Inventors:
Christopher Joseph Schofield, Chia-Hua Ho, Alexander Wolf, Wei Ge
Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.
Abstract: The identification of pO2 lowering agents as transient hypoxia-inducers is disclosed herein. Provided is a method of enhancing the efficacy of a hypoxia-sensitive agent in a subject, by administering to the subject a therapeutically effective amount of the hypoxia-sensitive agent and a therapeutically effective amount of a pO2 lowering agent. Methods of treating a subject with a tumor, by administering to the subject a therapeutically effective amount of a pO2 lowering agent and a therapeutically effective amount of a hypoxia-sensitive agent are also disclosed.
Type:
Application
Filed:
April 20, 2012
Publication date:
February 13, 2014
Applicants:
H.Lee Moffitt Cancer Center and Research Institute, Inc., Human Services
Inventors:
Shingo Matsumoto, Robert J. Gillies, James B. Mitchell, Murali K. Cherukuri, Keita Saito